In Vivo Cardiac-specific Expression of Adenylyl Cyclase 4 Gene Protects Against Klotho Deficiency-induced Heart Failure
Overview
Authors
Affiliations
Klotho is an aging-suppressor gene. Klotho gene deficiency causes heart failure in Klotho-hypomorphic mutant (KL (-/-)) mice. RNA-seq and western blot analysis showed that adenylyl cyclase type IV (AC4) mRNA and protein expression was largely decreased in cardiomyocytes of KL (-/-) mice. The objective of this study was to investigate whether in vivo cardiac-specific expression of AC4 gene protects against Klotho deficiency-induced heart failure. Interestingly, in vivo AAV-based cardiac-specific AC4 gene expression increased left ventricular fractional shortening, ejection fraction, stroke volume, and left ventricular end-diastolic volume in KL (-/-) mice, suggesting that cardiac-specific AC4 gene expression improves Klotho deficiency-induced heart dysfunction. Cardiac-specific AC4 gene expression also decreased Klotho deficiency-induced cardiac hypertrophy. Cardiac-specific AC4 gene expression alleviated Klotho deficiency-induced cardiac fibrosis and calcification. Furthermore, cardiac-specific AC4 gene expression attenuated mitochondrial dysfunction, superoxide accumulation and cardiomyocyte apoptotic cell death. Thus, downregulation of AC4 may contribute to Klotho deficiency-induced heart failure. Mechanistically, AAV2/9-αMHC-AC4 increased cardiomyocytic cAMP levels and thus regulated the PKA-PLN-SERCA2 signal pathway, which is critical in modulating calcium flux and mitochondrial function. In conclusion, cardiac-specific AC4 gene expression protects against Klotho deficiency-induced heart failure through increasing cardiomyocytic cAMP levels, which alleviates cAMP-dependent mitochondrial dysfunction, superoxide accumulation and apoptotic cell death. AC4 regulates superoxide levels via the cAMP-PKA pathway. AC4 could be a potential therapeutic target for heart failure associated with Klotho deficiency. Heart failure is the major cause of mortality in patients with chronic kidney disease (CKD). A decrease in Klotho levels is linked to CKD.
Crosswhite P, Sun Z Antioxidants (Basel). 2024; 13(6).
PMID: 38929115 PMC: 11200563. DOI: 10.3390/antiox13060677.
Kitaeva K, Solovyeva V, Blatt N, Rizvanov A Int J Mol Sci. 2024; 25(1).
PMID: 38203812 PMC: 10778954. DOI: 10.3390/ijms25010643.
KDM6A Demethylase Regulates Renal Sodium Excretion and Blood Pressure.
Han X, Akinseye L, Sun Z Hypertension. 2024; 81(3):541-551.
PMID: 38164755 PMC: 10922853. DOI: 10.1161/HYPERTENSIONAHA.123.22026.
Chen J, Lin Y, Sun Z Mol Med. 2023; 29(1):24.
PMID: 36809926 PMC: 9945614. DOI: 10.1186/s10020-023-00619-4.
Impact of Ninjin'yoeito on frailty and short life in klotho-hypomorphic (kl/kl) mice.
Amitani H, Chiba S, Amitani M, Michihara S, Takemoto R, Han L Front Pharmacol. 2022; 13:973897.
PMID: 36353482 PMC: 9637981. DOI: 10.3389/fphar.2022.973897.